e currency prices- Top See results about

The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.The main reason is that yesterday's mood was too high, and the organization just had to wait until it calmed down before doing more. Of course, there will be another understanding, that is, the unexpected benefits will make some institutions empty, so some institutions need to continue to collect chips.Now it is the hope of the above that the stock market will rise, and that technology and consumption will rise. This is not difficult to understand. What is difficult is whether you have the patience and confidence to hold these.

Although many people are still pessimistic, I am confident that the trend is bullish. Ups and downs will make many people lose money. Everyone will never make money outside their own cognition. It is better to wait patiently in the direction of their own cognition.At this time, institutions will either choose some high dividends or some oversold industry leaders as a defense. Those who want to catch the daily limit and buy and sell in day trading are more likely to lose money.Strategically speaking, today's index should be a weak rebound, so the index surprise is not expected.

Second, you must have the patience to hold shares. I told you in early trading that the market in December may be difficult as a whole, not to say that the index risk is great. Under the tone of stabilizing the stock market, there will be no big risk as a whole, but it is uncomfortable for those with high speculation.Everyone still tries to choose the direction of holding shares and wait patiently for the policy to be fulfilled.The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.